SCHEMBL12464366

SCHEMBL12464366

CC(C)n1cnc2cc(O)c(O)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.53
RAB9A P51151 7/20 0.48
KDM4E B2RXH2 5/20 0.48
GFER P55789 2/20 0.48
FGFR1 P11362 2/20 0.46
SRC P12931 2/20 0.46
NPC1 O15118 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.40
ALDH1A1 P00352 4/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.38
TP53 P04637 2/20 0.36
HSD17B10 Q99714 2/20 0.35
IDE P14735 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
PLAA Q9Y263 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7724928 0.78 POLB (0.56) HCAR3RAB9AKDM4EGFERNPC1
SCHEMBL12730480 0.78 HCAR3 (0.62) HCAR3RAB9AKDM4EGFERFGFR1
SCHEMBL23063551 0.78 HCAR3 (0.50) HCAR3RAB9AKDM4EGFERFGFR1
SCHEMBL12747298 0.77 HCAR3 (0.49) HCAR3RAB9AKDM4EGFERNPC1
SCHEMBL14726018 0.77 HCAR3 (0.49) HCAR3RAB9AKDM4EGFERNPC1
SCHEMBL18937427 0.74 FGFR1 (0.51) HCAR3RAB9AKDM4EGFERFGFR1
SCHEMBL2270041 0.74 FGFR1 (0.50) RAB9AKDM4EGFERFGFR1SRC
SCHEMBL4955288 0.73 FGFR1 (0.42) HCAR3RAB9AKDM4EGFERFGFR1
SCHEMBL4956118 0.73 FGFR1 (0.42) HCAR3RAB9AKDM4EGFERFGFR1
SCHEMBL17563260 0.73 HCAR3 (0.45) HCAR3RAB9AKDM4EGFERNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 US disclosed
WO-2018075947-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-04-26 WO disclosed
US-9416155-B2 Direct sensing of molecular species by polyfluors on a DNA backbone THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-08-16 US disclosed
US-20120309107-A1 Direct Sensing of Molecular Species by Polyfluors on a DNA Backbone THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2012-12-06 US disclosed
WO-2011081939-A1 DIRECT SENSING OF MOLECULAR SPECIES BY POLYFLUORS ON A DNA BACKBONE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309107-A1 Direct Sensing of Molecular Species by Polyfluors on a DNA Backbone ERCC4, POLL, POLQ HCAR3 833/4885RAB9A 4737/4885KDM4E 4349/4885
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 HCAR3 3757/4885RAB9A 2724/4885KDM4E 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.